

Rapid Expansion of Human Adipose Stem Cells using Corning® HYPERFlask® Cell Culture Vessel

Customer Application Note

CORNING

N.M. Vieira, V. Brandalise, E. Zucconi, M. Secco, M. Zatz
Human Genome Research Center
Biosciences Institute, University of São Paulo
São Paulo, Brazil

Abstract

Human Adipose Stem Cells (hASCs) represent an abundant and accessible source of multipotent adult cell population (1). Although liposuction fat can be obtained in large quantities, the large number of viable and undifferentiated cells required for cellular therapeutic applications will need efficient *in vitro* expansion methods. For instance, in an experimental therapeutic trial in a mouse model for progressive muscular dystrophy, we obtained positive results when we injected 10^6 cells monthly (2). If we extrapolate for human use, an estimated quantity of stem cells for a person weighing about 60 kg would be about 3×10^9 cells per month. We have tested several protocols for *ex vivo* expansion, and using Corning HYPERFlask cell culture vessels, we were able to generate a great quantity of mesenchymal stem cells for research, as well as aiming future cellular therapeutic approaches.

Results

hASCs were isolated from adipose tissue obtained from elective liposuction procedures. After isolation, hASCs were characterized by flow cytometry for the expression of 12 cell surface proteins. Myogenic, adipogenic, chondrogenic and osteogenic differentiation was demonstrated by the expression of myogenic markers, lipid vacuoles, mucopolysaccharide-rich extracellular matrix and calcium deposits, respectively (1,2).

hASCs are easy to expand in HYPERFlask vessels (Fig. 1) and show a fibroblast-like morphology consistent with that of hASCs cultured in T-175 flasks with vent caps (Fig. 2). Cells were cultured with the standard proliferation media (Dulbecco's modified Eagle's media – high glucose containing 10% FBS) for hASCs, and an initial seeding inoculum of 1.72×10^7 per HYPERFlask vessel. Cultures were harvested

using PBS and TrypLE™ (Invitrogen™). Cells were counted by Guava® EasyCyte™ using the Guava ViaCount reagent. After expansion using HYPERFlask vessels, hASCs maintained their immunophenotype and multilineage differentiation




Figure 1. Corning HYPERFlask Cell Culture Vessel Principal of Operation. Ten equivalent layers, each containing the same surface area of a gas-permeable material, are joined together to form a multi-layered cell culture vessel.




Figure 2. Typical morphology of hASCs in A) T-175 flasks and in B) HYPERFlask vessel, 45 minutes after seeding.

potential. hASCs did not express endothelial markers (CD31- PECAM1), nor hematopoietic markers (CD34, CD45 and CD117-c-kit). The majority of hASCs expressed high levels of CD13, CD44, adhesion markers (CD29-integrin β 1, CD90-Thy-1), and mesenchymal stem cell

marker CD73 (SH3). Expression of some markers, such as CD105 (SH2), was variable among the donors. hASCs were negative for HLA-class II (HLA-DR) but positive for HLA-class I (HLA-ABC) (Fig. 3).




Figure 3. Immunophenotyping of hASCs cells after expansion in HYPERFlask® vessels. Values represent the mean percentage of all assessed cells positively stained by the indicated antigens and analyzed by flow cytometry. Graphics show forward scatter versus fluorescence intensity.

Adipogenic, chondrogenic, and osteogenic differentiation was demonstrated by the expression of lipid vacuoles, mucopolysaccharide-rich extracellular matrix and calcium deposits, respectively (Fig. 4). These results confirmed the mesenchymal nature of the expanded cells, as well as their multipotent potential.

Conclusion and Prospective Research

The results from the present study demonstrate a strategy to expand viable and undifferentiated hASCs. *Ex vivo* expansion has been attempted in several ways such as static cultures combining growth factors, or mimicking the natural micro-environment using co-culture systems. We used the standard proliferation media for hASCs and an initial seeding inoculum of 1.72×10^7 per Corning® HYPERFlask® vessel. After 7 days, we obtained 1.72×10^8 cells per flask. These cells may be injected or inoculated into a larger-scale vessel, such as Corning CellSTACK® chambers or a bioreactor, to be further expanded. With this approach, we were able to generate a great quantity of mesenchymal stem cells for research, as well as aiming future cellular therapeutic approaches.

References

1. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. *Tissue Eng.* 2001; 7:211-228.
2. Vieira NM, Bueno Jr CR, Brandalise V, et al. SJL dystrophic mice express a significant amount of human muscle proteins following systemic delivery of human adipose-derived stromal cells without immunosuppression. *Stem Cells.* 2008; 26:2391-2398.




Figure 4. Differentiation potential of hASCs after expansion in HYPERFlask vessels.

For additional product or technical information, please visit www.corning.com/lifesciences or call 1.800.492.1110. Outside the United States, please call 978.442.2200.

CORNING

Corning Incorporated *Life Sciences*

Tower 2, 4th Floor
900 Chelmsford St.
Lowell, MA 01851
t 800.492.1110
t 978.442.2200
f 978.442.2476

www.corning.com/lifesciences

Worldwide Support Offices

ASIA / PACIFIC

Australia/New Zealand
t 0402-794-347

China
t 86-21-5467-4666
f 86-21-5407-5899

India
t 91 124 4604000
f 91 124 4604099

Japan
t 81 3-3586 1996
f 81 3-3586 1291

Korea
t 82 2-796-9500
f 82 2-796-9300

Singapore
t 65 6733-6511
f 65 6861-2913

Taiwan
t 886 2-2716-0338
f 886 2-2716-0339

EUROPE

France
t 0800 916 882
f 0800 918 636

Germany
t 0800 101 1153
f 0800 101 2427

The Netherlands
t 31 20 655 79 28
f 31 20 659 76 73

United Kingdom
t 0800 376 8660
f 0800 279 1117

**All Other European
Countries**
t 31 (0) 20 659 60 51
f 31 (0) 20 659 76 73

LATIN AMERICA

Brasil
t (55-11) 3089-7419
f (55-11) 3167-0700

Mexico
t (52-81) 8158-8400
f (52-81) 8313-8589